JACC: CardioOncology Impact Factor

The first thing the metric tells you is that the journal has moved quickly into the top tier of its lane. That matters more here than it would for a very old flagship. JACC: CardioOncology is young, so a double-digit JIF is a signal that the field is citing its better papers quickly and repeatedly.

The second thing it tells you is that the journal's audience is specific and valuable. A paper published here is not just getting cardiology attention or oncology attention in isolation. It is reaching the exact readership that thinks about cardiovascular toxicity, prevention, survivorship, therapeutics, and clinical decision-making in patients with cancer.

The more important point, though, is what the number does not tell you. It does not tell you whether your manuscript is truly cardio-oncology. That remains the first editorial gate.

The JCR impact factor is the authoritative metric on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy for this relatively new journal.

Directionally, the open citation signal is up from 4.13 in 2022 to 5.11 in 2024, with almost no drop year over year from 2023 to 2024. That stability matters. It suggests the journal's rise was not just one temporary citation spike. It is holding its position as the field matures.

For a journal this new, that is a strong sign of institutional ownership and audience trust.

The common mistake is to see the JACC masthead, the 13.4 JIF, and the oncology overlap and assume any cardiovascular paper in cancer or any cancer paper with cardiac readouts belongs here.

That is not how the journal is framed publicly, and it is not how editors usually screen it. The official guidance is unusually direct that manuscripts should answer one question: how does the work potentially impact the clinical care of cancer patients?

That means the journal generally rewards papers where:

• the cardio-oncology audience is obvious on first read
• the care consequence is explicit rather than implied
• the translational or clinical implication is load-bearing
• the overlap between oncology and cardiovascular medicine is central, not decorative

If the paper earns its cardio-oncology identity only in the discussion, the metric will flatter the fit more than the journal will.

In our pre-submission review work on manuscripts targeting JACC: CardioOncology, the repeat problem is not low-quality science. It is misowned science.

We see strong studies that touch cancer and cardiovascular disease, but the paper has not yet decided whether it is truly solving a cardio-oncology problem. Editors actually screen for that distinction, and the journal's public calls for papers and author guidance reinforce it.

In our pre-submission review work on manuscripts targeting JACC: CardioOncology, four failure patterns recur.

The manuscript has overlap without ownership. It contains cancer context and cardiovascular endpoints, but the specialist readership case is still vague.

The care consequence is one step too indirect. This is common in biomarker, outcomes, and epidemiology papers. The result is interesting, but the reader still has to infer what changes for cardio-oncology care.

The article type is doing too much work. We see papers forced into a format because the topic sounds right, even though the story still reads more like general cardiology or general oncology.

The first read undersells the audience. The title and abstract can bury a solid specialist paper if they make the crossover logic feel secondary.

If that sounds familiar, a JACC: CardioOncology submission readiness check is usually more useful than another round of cosmetic editing.

The impact factor does not tell you whether the paper is specialist enough, whether the clinical consequence is visible quickly enough, or whether the manuscript is really owned by cardio-oncology rather than by general cardiology or oncology.

That is the main reason authors misread the journal. The metric confirms status. It does not close the gap between topic overlap and true editorial fit.